2096455-90-0

物理化学性质
储存条件 | -20°C储存 |
溶解度 | DMSO : ≥ 83.33 mg/mL (224.16 mM) |
形态 | Solid |
颜色 | White to off-white |
2096455-90-0价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 5mg | 800元 |
2025/02/08 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 10mM * 1mLin DMSO | 880元 |
2025/02/08 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 10mg | 1200元 |
常见问题列表
Ki: 2.4 nM (H4R bind), 1.56 nM (H4R func)
Adriforant is tested and observed binding K i =2.4 nM and functional K i =1.56 nM for H4R. Data from functional assays produce convergent projections of the free plasma efficacious concentration and Adriforant (Compound 13) is fast on/fast off on rhH4R. The in vitro IC 50 on human native isolated eosinophils assessing actin polymerisation is 1.16 nM and assuming need 10 times the IC 50 for >90% receptor occupancy (and therefore near complete inhibition of the response) suggested a concentration of 12 nM. The data in the whole blood GAFS assay demonstrates that the imetit induced shape change is completely blocked at a total blood concentration of 30 nM (which correcting for PPB and blood partitioning equates to approximately 10 nM free). For the purpose of dose projection and safety margin calculation, a Ceff/Cmin concentration of 10-15 nM is used.